Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Chinook launches to develop kidney disease drugs

by Michael McCoy
August 30, 2019 | A version of this story appeared in Volume 97, Issue 34

Chinook Therapeutics has launched with $65 million in series A funding to develop small-molecule drugs for kidney diseases. The firm was incubated in Versant Venture’s Inception Sciences center in Vancouver, British Columbia, and is led by several veterans of big pharma and biotech firms. Chinook says it will use single-cell RNA sequencing, human-derived organoids, and new translational methods to discover drugs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.